The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The American College of Clinical Pharmacy is approved by BPS as a provider for the recertification of BCPS.
BPS is an autonomous division of the American Pharmacists Association. To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for board certification examinations. BPS, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. BPS is totally separate and distinct from ACCP. For information about BPS specialty recertification the BPS recertification process, go to: www.bpsweb.org/
To receive recertification credit, posttests must be submitted prior to the recertification posttest deadline (see above). Only completed tests are eligible for credit; no partial or incomplete tests will be processed. You may complete one or all available posttests for credit.
The passing point to earn recertification credit is based on an expert analysis of the assessment items in each posttest. Any posttest submitted before the recertification test deadline that meets this passing point will earn recertification credits. These credits will be assigned as of the date of test submission and reported within 48 hours to BPS. For statements of recertification credit, visit www.bpsweb.org.
In accordance with BPS guidelines concerning remediation for products launched in 2024 and after, posttests that do not reach the passing point for recertification credit will generate a second-chance test option. This test will automatically appear in the learner’s My Account page and will have assessment items presented in a different order. To qualify for recertification credit, the second-chance test must be submitted before the recertification deadline stated above.
The ACCP Recertification Dashboard is a free online tool that can track recertification credits as they are earned through ACCP and schedule new opportunities for credits from upcoming ACCP professional development programs. Questions regarding the number of hours required for recertification should be directed to BPS at www.bpsweb.org.
Target Audience: The target audience for Clinical Reasoning Series in Pharmacotherapy is the pharmacist practicing in a clinical setting as a Board-Certified Pharmacotherapy Specialist (BCPS), looking to earn recertification credit, and those clinicians seeking additional information on the topics covered.
Target on Oncology Pharmacotherapy: Updates, Safety, and Management of Immune Checkpoint Inhibitor and Immune Effector Cell TherapiesActivity Number: 0217-0000-25-108-H01-P
Contact Hour(s): 1.50
Activity Type: Application BasedLearning Objectives1. Compare mechanism and indications between immune checkpoint inhibitor and immune effector cell therapies.
2. Recognize presentation of immune checkpoint inhibitor-related toxicity in commonly involved organ systems.
3. Design a therapeutic monitoring plan for immune checkpoint inhibitor therapy.
4. Differentiate the presentation of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
5. Formulate a management strategy for toxicity related to immune effector cell therapy. |
Revolutionizing Pulmonary Care: Integrating Medication Management into PracticeActivity Number: 0217-0000-25-109-H01-P
Contact Hour(s): 1.50
Activity Type: Application BasedLearning Objectives1. Differentiate the clinical features and management approaches of asthma, chronic obstructive pulmonary disease (COPD), and ‘asthma-COPD overlap.’
2. Review newly approved and emerging treatment options for asthma and COPD.
3. Formulate a plan for implementing current guideline-recommended immunizations into comprehensive pulmonary care.
4. Evaluate the benefit of weight loss treatment in obese patients with obstructive sleep apnea.
5. Design an individualized treatment plan for a patient with comorbid pulmonary conditions. |
Managing Risk: Transitions in Antithrombotic Therapy and Lipid Medication ManagementActivity Number: 0217-0000-25-110-H01-P
Contact Hour(s): 3.00
Activity Type: Application BasedLearning Objectives1. Distinguish between available antiplatelet medication options for the treatment of acute coronary syndromes.
2. Evaluate upstream antiplatelet administration timing as a dosing strategy for NSTE-ACS.
3. Apply ischemic and bleeding risk scoring tools to inform dosing strategies.
4. Choose the best dosing strategies for individual patient care scenarios.
5. Identify comprehensive care plans that integrate cardiovascular, kidney, and metabolic targets for patients with complex conditions using recommendations from the American Heart Association's Presidential Advisory.
6. Identify key factors influencing the predictive accuracy of the pooled cohort equations vs. the PREVENT model in predicting cardiovascular risk in select populations.
7. Determine how global coronary artery calcium guidelines can be applied in clinical practice to improve patient outcomes.
8. Evaluate emerging therapeutic strategies targeting Lipoprotein(a) and their potential impact on reducing cardiovascular events in high-risk patients. |
The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.